272 related articles for article (PubMed ID: 27161872)
1. Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.
Levin N; Spencer A; Harrison SJ; Chauhan D; Burrows FJ; Anderson KC; Reich SD; Richardson PG; Trikha M
Br J Haematol; 2016 Sep; 174(5):711-20. PubMed ID: 27161872
[TBL] [Abstract][Full Text] [Related]
2. Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide.
Das DS; Ray A; Song Y; Richardson P; Trikha M; Chauhan D; Anderson KC
Br J Haematol; 2015 Dec; 171(5):798-812. PubMed ID: 26456076
[TBL] [Abstract][Full Text] [Related]
3. Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results.
Harrison SJ; Mainwaring P; Price T; Millward MJ; Padrik P; Underhill CR; Cannell PK; Reich SD; Trikha M; Spencer A
Clin Cancer Res; 2016 Sep; 22(18):4559-66. PubMed ID: 27117181
[TBL] [Abstract][Full Text] [Related]
4. Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo.
Manton CA; Johnson B; Singh M; Bailey CP; Bouchier-Hayes L; Chandra J
Sci Rep; 2016 Jan; 6():18953. PubMed ID: 26804704
[TBL] [Abstract][Full Text] [Related]
5. [Proteasome inhibitors in cancer therapy].
Romaniuk W; Ołdziej AE; Zińczuk J; Kłoczko J
Postepy Hig Med Dosw (Online); 2015 Dec; 69():1443-50. PubMed ID: 27259216
[TBL] [Abstract][Full Text] [Related]
6. Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier.
Di K; Lloyd GK; Abraham V; MacLaren A; Burrows FJ; Desjardins A; Trikha M; Bota DA
Neuro Oncol; 2016 Jun; 18(6):840-8. PubMed ID: 26681765
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model.
Singh AV; Palladino MA; Lloyd GK; Potts BC; Chauhan D; Anderson KC
Br J Haematol; 2010 May; 149(4):550-9. PubMed ID: 20331453
[TBL] [Abstract][Full Text] [Related]
8. Comparative mechanisms of action of proteasome inhibitors.
Wang M
Oncology (Williston Park); 2011 Nov; 25 Suppl 2():19-24. PubMed ID: 25188479
[TBL] [Abstract][Full Text] [Related]
9. Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay.
Lee SJ; Levitsky K; Parlati F; Bennett MK; Arastu-Kapur S; Kellerman L; Woo TF; Wong AF; Papadopoulos KP; Niesvizky R; Badros AZ; Vij R; Jagannath S; Siegel D; Wang M; Ahmann GJ; Kirk CJ
Br J Haematol; 2016 Jun; 173(6):884-95. PubMed ID: 27071340
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
Zang M; Li Z; Liu L; Li F; Li X; Dai Y; Li W; Kuckelkorn U; Doeppner TR; Hermann DM; Zhou W; Qiu L; Jin F
Cancer Lett; 2015 Oct; 366(2):173-81. PubMed ID: 26116344
[TBL] [Abstract][Full Text] [Related]
11. Marizomib, a potent second generation proteasome inhibitor from natural origin.
Ma L; Diao A
Anticancer Agents Med Chem; 2015; 15(3):298-306. PubMed ID: 25403165
[TBL] [Abstract][Full Text] [Related]
12. Second Generation Proteasome Inhibitors in Multiple Myeloma.
Gozzetti A; Papini G; Candi V; Brambilla CZ; Sirianni S; Bocchia M
Anticancer Agents Med Chem; 2017; 17(7):920-926. PubMed ID: 27592543
[TBL] [Abstract][Full Text] [Related]
13. Proteasome inhibition correlates with intracellular bortezomib concentrations but not with antiproliferative effects after bolus treatment in myeloma cell lines.
Dettmer S; Theile D; Schäfer J; Seckinger A; Burhenne J; Weiss J
Naunyn Schmiedebergs Arch Pharmacol; 2016 Oct; 389(10):1091-101. PubMed ID: 27422413
[TBL] [Abstract][Full Text] [Related]
14. Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors.
Besse A; Besse L; Kraus M; Mendez-Lopez M; Bader J; Xin BT; de Bruin G; Maurits E; Overkleeft HS; Driessen C
Cell Chem Biol; 2019 Mar; 26(3):340-351.e3. PubMed ID: 30612952
[TBL] [Abstract][Full Text] [Related]
15. New proteasome inhibitors in myeloma.
Lawasut P; Chauhan D; Laubach J; Hayes C; Fabre C; Maglio M; Mitsiades C; Hideshima T; Anderson KC; Richardson PG
Curr Hematol Malig Rep; 2012 Dec; 7(4):258-66. PubMed ID: 23065395
[TBL] [Abstract][Full Text] [Related]
16. Apigenin, chrysin, and luteolin selectively inhibit chymotrypsin-like and trypsin-like proteasome catalytic activities in tumor cells.
Wu YX; Fang X
Planta Med; 2010 Feb; 76(2):128-32. PubMed ID: 19653143
[TBL] [Abstract][Full Text] [Related]
17. Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
Potts BC; Albitar MX; Anderson KC; Baritaki S; Berkers C; Bonavida B; Chandra J; Chauhan D; Cusack JC; Fenical W; Ghobrial IM; Groll M; Jensen PR; Lam KS; Lloyd GK; McBride W; McConkey DJ; Miller CP; Neuteboom ST; Oki Y; Ovaa H; Pajonk F; Richardson PG; Roccaro AM; Sloss CM; Spear MA; Valashi E; Younes A; Palladino MA
Curr Cancer Drug Targets; 2011 Mar; 11(3):254-84. PubMed ID: 21247382
[TBL] [Abstract][Full Text] [Related]
18. High chymotrypsin-like activity in the plasma of patients with newly diagnosed multiple myeloma treated with bortezomib is predictive of a better response and longer PFS.
Romaniuk W; Bolkun L; Kalita J; Galar M; Bernatowicz M; Ostrowska H; Kloczko J
Ann Hematol; 2018 Oct; 97(10):1879-1887. PubMed ID: 29946907
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma.
Kegyes D; Gulei D; Drula R; Cenariu D; Tigu B; Dima D; Tanase A; Badelita S; Buzoianu AD; Ciurea S; Ghiaur G; Terpos E; Ciechanover A; Einsele H; Tomuleasa C
Blood Rev; 2023 Sep; 61():101100. PubMed ID: 37291017
[TBL] [Abstract][Full Text] [Related]
20. Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma.
Kubiczkova L; Pour L; Sedlarikova L; Hajek R; Sevcikova S
J Cell Mol Med; 2014 Jun; 18(6):947-61. PubMed ID: 24712303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]